Erasca (ERAS) Stock Forecast: StockMap's 2-Week Call
ERAS stock forecast: StockMap's model makes no two-week call on Erasca after the Nov 19 close: its evidence is split, 7 reasons for and 8 against. Right in 0 of 4 two-week windows on ERAS since Sep 9; by chance, a call on the same dates was right 28% of the time.
Erasca last closed at $14.22, +3.34% on the session.
Against the IVW growth benchmark the position is +5.67% over the forecast window.
Erasca's market cap is $4.99B as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 0 (too close to call).
Where ERAS sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 7 bullish and 8 bearish.
Agreement across those insights is 47%.
14 daily calls for ERAS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Erasca in the 13th percentile on return on equity, where 100 is best.
Erasca is classified under Health Care / Biotechnology.
StockMap tracks Erasca as the 47th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Erasca ranks 61st of 394 in the group, against a group median of -0.27.